Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14915108 | 1.00 | HRH3 (0.38) | HRH3DPP4DPP8DPP9HSD11B1 | |
| SCHEMBL30887719 | 1.00 | HRH3 (0.38) | HRH3DPP4DPP8DPP9HSD11B1 | |
| SCHEMBL35211076 | 0.81 | DPP4 (0.32) | DPP4DPP8DPP9 | |
| SCHEMBL31671020 | 0.81 | DPP4 (0.32) | DPP4DPP8DPP9 | |
| SCHEMBL5998295 | 0.79 | HRH3 (0.38) | HRH3 | |
| SCHEMBL806361 | 0.79 | HRH3 (0.38) | HRH3 | |
| SCHEMBL15047433 | 0.79 | HRH3 (0.38) | HRH3 | |
| SCHEMBL5971686 | 0.79 | HRH3 (0.38) | HRH3 | |
| SCHEMBL16279228 | 0.79 | HRH3 (0.38) | HRH3DPP4 | |
| SCHEMBL14744511 | 0.79 | DPP4 (0.37) | DPP4DPP8DPP9HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3205648-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205648-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2580210-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2580210-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9078871-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078871-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078871-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8703810-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703810-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703810-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2580210-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011156518-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156518-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | HRH3 1951/4885DPP4 1476/4885DPP8 839/4885 |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | HRH3 1919/4885DPP4 1440/4885DPP8 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.